$BSEM

BioStem Technologies (BSEM) expanded hospital access for VENDAJE and VENDAJE AC through contracts with Vizient and Premier, two large U.S. GPOs. Both products are now available for order under these contracts. The move is expected to support BioStem's commercial strategy and broaden its wound care product reach. BSEM shares closed at $3.61 on Thursday and were up 9.42% in premarket trading.

BioStem Technologies (BSEM) reported Q2 2026 revenue of $7.9M, up 29% sequentially, driven by Neox and Clarix product sales. The company raised full-year 2026 revenue guidance to $26M-$29M and uplisted to Nasdaq. BSEM also completed a $2.5M private placement and held $7.0M in cash as of Q2 2026.

BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) — BioSt

BioStem Technologies Inc. (OTC: BSEM) said it filed a Form 10 registration statement with the SEC to register its common stock and reaffirmed plans to pursue a Nasdaq listing. The filing is not yet effective and will become effective after SEC review. Until uplisting, BSEM shares continue trading on the OTC market.

POMPANO BEACH, Fla., April 21, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( OTC: BSEM ) , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive ...

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, marking the fourth consecutive quarter of profitability